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TP53 mutant cell lines selected for resistance 
to MDM2 inhibitors retain growth inhibition 
by MAPK pathway inhibitors but a reduced 
apoptotic response
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Abstract 
Background: Emergence of resistance to molecular targeted therapy constitutes a limitation to clinical benefits in 
cancer treatment. Cross‑resistance commonly happens with chemotherapeutic agents but might not with targeted 
agents.
Methods: In the current study, TP53 wild‑type cell lines with druggable MAPK pathway mutations [BRAFV600E (WM35) 
or NRAS Q61K (SJSA‑1)] were compared with their TP53 mutant sublines (WM35‑R, SN40R2) derived by selection for 
resistance to MDM2/p53 binding antagonists.
Results: The continued presence of the druggable MAPK pathway targets in the TP53 mutant (TP53MUT) WM35‑
R and SN40R2 cells was confirmed. Trametinib and vemurafenib were tested on the paired WM35/WM35‑R and 
SJSA‑1/SN40R2 cells and similar growth inhibitory effects on the paired cell lines was observed. However, apoptotic 
responses to trametinib and vemurafenib were greater in WM35 than WM35‑R, evidenced by FACS analysis and cas‑
pase 3/7 activity, indicating that these MAPK inhibitors acted on the cells partially through p53‑regulated pathways. 
SiRNA mediated p53 knockdown in WM35 replicated the same pattern of response to trametinib and vemurafenib as 
seen in WM35‑R, confirming that p53 plays a role in trametinib and vemurafenib induced apoptosis. In contrast, these 
differences in apoptotic response between WM35 and WM35‑R were not seen with the SJSA‑1/SN40R2 cell line pair. 
This is likely due to p53 suppression by overexpressed MDM2 in SJSA‑1.
Conclusion: The  TP53MUT cells selected by resistance to MDM2 inhibitors nevertheless retained growth inhibitory but 
not apoptotic response to MAPK pathway inhibitors.
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Background
RAS and RAF oncogenes are frequently mutated in 
human cancer leading to a constitutively activated 
MAPK pathway which is critical for oncogenesis, tumour 
proliferation and survival [1, 2]. These genetic alterations 
provide important targets druggable by low molecular 
weight compounds which have been evaluated in clinical 
trials and become licensed treatments. For example, the 
dual blockade of the MAPK pathway by the combination 
of BRAF and MEK inhibitors has become the standard 
treatment for unresectable or metastatic melanoma har-
boring a BRAFV600 mutation [3, 4]. Vemurafenib [5] and 
trametinib [6] are the first BRAF and MEK inhibitors 
respectively to be approved for BRAF-mutated cancer 
(melanoma). Trametinib strongly inhibits MEK1/2 kinase 
activities and was shown not to inhibit another 98 kinase 
activities [7]. Preclinical study of trametinib showed effi-
cacy against cancer cells with either BRAF or RAS muta-
tions and even on cancer cells with neither BRAF nor 
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RAS mutations [8]; therefore, cancers without BRAF 
mutations are included in clinical trials of trametinib.
Tumour protein p53, encoded by the tumour suppres-
sor gene TP53, is a transcription factor activating target 
genes that mediate various functions, including deoxy-
ribonucleic acid (DNA) repair, metabolism, cell cycle 
arrest, apoptosis, senescence and autophagy [9–11]. Loss 
of wild-type (WT) p53 function by either TP53 muta-
tions, or overexpression of its negative regulators such 
as MDM2, causes cancer cell development, survival, 
and proliferation [12]. MDM2-p53 binding antago-
nists are designed to occupy the p53-binding pocket of 
MDM2 and therefore stabilize p53 through prevention of 
MDM2-mediated ubiquitylation and proteasomal degra-
dation. MDM2-p53 binding antagonists cause cell cycle 
arrest, apoptosis, and growth inhibition of cancer cells 
resulting from activation of the p53 pathway in  p53WT 
(p53-wild type) cancer cells [13]. The first small molecule 
MDM2 inhibitor, Nutlin-3, showed efficacy in vitro and 
with tumour xenograft (SJSA-1) models in nude mice 
[14]. RG7388 [15] and HDM201 [16] are new generations 
of MDM2 inhibitors which are more potent and specific 
than Nutlin-3 and clinical trials are ongoing to investigate 
their efficacy in clinical settings.
Emergence of resistance to molecular targeted therapy 
constitutes a limitation to maintained clinical benefits 
in cancer treatment. Cross-resistance commonly hap-
pens with chemotherapeutic agents. After selection for 
resistance to a single drug, cells frequently also show 
cross-resistance to other structurally and mechanistically 
unrelated drugs by increasing the activity of efflux pumps 
(p-glycoprotein, PGP, also known as multidrug resistance 
protein 1, MDR-1; multidrug-resistance-associated pro-
tein 1, MRP-1) or reducing drug influx, or other mecha-
nisms [17].
Unlike cytotoxic agents, resistance to targeted ther-
apy usually results from mutation of the target gene 
or activation of pro-survival signaling pathways [18]. 
Because of the different resistance mechanisms involved, 
cross-resistance might play less of a role in targeted 
therapy than with cytotoxic agents. The evidence for 
cross-resistance of targeted therapies, particularly for 
MDM2 inhibitors is lacking. Michaelis et  al. selected 
p53 mutant (P53MUT) cells (UKF-NB-3r  Nutlin10μM) by 
continuous exposure to Nutlin-3 and found the resistant 
cells displayed a multi-drug resistant phenotype which 
was resistant to various cytotoxic drugs and irradiation 
[19]. By contrast, another study showed the resistant 
cells (S_N40R2, N_N20R1) selected by Nutlin-3 retained 
sensitivity to ionizing radiation [20]. Previous studies 
have focused on the cross-resistance between MDM2 
inhibitors and cytotoxic agents and irradiation, but to 
date  no reported studies have investigated the response 
to alternative effective small molecule targeted agents in 
cells selected for resistance to MDM2 inhibitors.
The aim of the current study was to select cell lines 
with resistance to MDM2/p53 binding antagonists from 
cancer cells with druggable targets of the MAPK pathway 
resulting from either BRAFV600E (WM35) or NRASQ61K 
(SJSA-1) mutation and to examine whether the MDM2 
inhibitor-resistant cell lines retain sensitivity to the 
MAPK pathway inhibitors, vemurafenib and trametinib.
Methods
Cell lines and reagents
Two parental and MDM2 inhibitor resistant cell line 
pairs, WM35/WM35-R and SJSA-1/SN40R2, were rou-
tinely cultured using Dulbecco’s modified Eagle’s medium 
(DMEM) medium and RPMI-1640 medium (Sigma, Dor-
set, UK) respectively, which were supplemented with 10% 
(v/v) foetal calf serum. All the cell lines were authenti-
cated by serial tandem repeat (STR) profiling (WM35, 
WM35-R by NewGene, Newcastle, UK; SJSA-1, SN40R2 
by LGC Standards). Nutlin-3 was purchased from New-
Chem (Newcastle, UK), RG7388 and HDM201 were 
obtained by custom synthesis via Astex Pharmaceuticals. 
Trametinib and vemurafenib were obtained from Cam-
bridge Bioscience. All compounds were initially dissolved 
in dimethyl sulfoxide (DMSO) (Sigma-Aldrich) and used 
to dose cells at a final concentration of 0.5% DMSO, 
optimised to give minimal cytotoxic effects on cells, and 
0.5% DMSO only solvent controls were included in all 
experiments.
Growth inhibition assay
Cells were seeded in 96-well plates overnight and treated 
with indicated drugs for 72 h. The cells were fixed using 
Carnoy’s fixative followed by Sulforhodamine B (SRB) 
assay [21]. A spectrophotometer (Spectramax250 Molec-
ular Devices) was used to measure absorbance at 570 nm. 
The  GI50 value was determined by the concentration of a 
compound which can reduce the growth of the cell popu-
lation by 50% compared to untreated control cultures 
after subtraction of baseline seeded cell amount prior to 
the start of treatment [22].
Immunoblotting
Cells lysates were harvested by scraping and suspension 
in lysis buffer (62.5  mM Tris HCl/pH 6.8, 10% glycerol 
and 2% SDS), heated and sonicated. The protein concen-
trations of the cell lysates were estimated using a  Pierce® 
BCA Protein Assay kit. Equal quantities of protein were 
loaded onto and separated by SDS–polyacrylamide gels 
(4–20% Mini-PROTEAN® TGX™ Gel, BioRad). The sep-
arated proteins were transferred and immobilized onto 
Amersham™ nitrocellulose membranes (GE Healthcare 
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Life Science). Primary antibodies against p53 (DO-7) 
(#M7001, Dako), MDM2 (Ab-1) (#OP46, Merck Mil-
lipore),  p21WAF1 (EA10) (#OP64, Calbiochem), p-ERK 
(E-4) (sc-7383, Santa Cruz), ERK (K-23) (sc-94, Santa 
Cruz), GAPDH (14C10) (#2118, Cell Signaling Technol-
ogy),  BRAFV600E (VE1, Spring Bioscience), Actin (A4700, 
Sigma) and secondary goat anti-mouse/rabbit horserad-
ish peroxidase-conjugated antibodies (#P0447/P0448, 
Dako) were used. All antibodies were diluted in 5% (w/v) 
non-fat milk or BSA in TBS-tween (20 mM Tris/pH 6.8, 
137 mM NaCl, 0.1% tween-20). Protein signals were visu-
alized using enhanced chemiluminescence (GE Health-
care Life Sciences) and X-ray film (Fujifilm).
RNA extraction and qRT‑PCR (quantitative real‑time 
polymerase chain reaction)
Total RNA was extracted using an RNeasy Mini Kit (Qia-
gen, Germany). RNA purity and concentration were esti-
mated with an ND-1000 spectrophotometer (NanoDrop 
Technologies, Thermo Scientific, UK). Complementary 
DNA was generated using the High-Capacity cDNA 
Reverse Transcription Kit (4368814, Thermo Fisher Sci-
entific) as described by the manufacturer. qRT-PCR was 
carried out using SYBR green RT-PCR master mix (Life 
Technologies) as per the manufacturer’s guidelines and 
the following primers:
MDM2: F-AGT AGC AGT GAA TCT ACA GGGA, 
R-CTG ATC CAA CCA ATC ACC TGAAT 
CDKN1A: F-TGT CCG TCA GAA CCC ATG C, 
R-AAA GTC GAA GTT CCA TCG CTC 
PUMA: F-ACC TCA ACG CAC AGT ACG A, R-CTG 
GGT AAG GGC AGG AGT C
BAX: F-CCC GAG AGG TCT TTT TCC GAG, R-CCA 
GCC CAT GAT GGT TCT GAT 
PIG-3: F-AGC GAG GAA GTC TGA TCA CC, R-CGT 
GGA GAA GTG AGG CAG AA
AEN: F-CTT CCA GGC GCT CAA GTA TGT, R-GGG 
CCA GGT CCT TTA GAG AGA 
FDXR: F-CAG CAT TGG GTA TAA GAG CCG, 
R-GGC CTG GCA CAT CCA TAA CC
TNFRSF10B: F-ATG GAA CAA CGG GGA CAG AAC, 
R-CTG CTG GGG AGC TAG GTC T
TP53INP1: F-TCT TGA GTG CTT GGC TGA TACA, 
R-GGT GGG GTG ATA AAC CAG CTC 
TP53: F-CAG CAC ATG ACG GAG GTT GT, R-TCA 
TCC AAA TAC TCC ACA CGC 
GAPDH: F-CAA TGA CCC CTT CAT TGA CC, 
R-GAT CTC GCT CCT GGA AGA T.
A total of 10 ng of the cDNA samples per 10 µL final 
reaction volume, with the standard cycling parameters 
(stage 1: 50 °C for 2 min, stage 2: 95 °C for 10 min, then 
40 cycles of 95 °C for 15 s, and 60 °C for 1 min), were set 
and carried out on an ABI 7900HT sequence detection 
system. GAPDH was used as endogenous control and 
samples of cells exposed to DMSO carrier were used as 
the calibrator for each independent repeat, with the for-
mula  2ΔΔCt used to calculate fold-changes. Analysis was 
carried out using SDS 2.3 software (Applied Biosystems).
Fluorescence‑activated cell sorting (FACS)
After treatment, floating and adhered cells were pooled 
and fixed using 70% cold ethanol. Samples were incu-
bated in 250  μL PBS with 40  μg/mL propidium iodide 
(Sigma-Aldrich), 20 μg/mL RNAse A (Sigma-Aldrich) for 
20 min in the dark at room temperature, then were ana-
lyzed on a FACSCaliburTM flow cytometer using Cell-
Quest Pro software (Becton–Dickinson, Oxford, UK). 
Cell cycle distribution based on DNA content was deter-
mined using Cyflogic (CyFlo Ltd, Turku, Finland).
Caspase 3/7 activity assay
Melanoma cells were seeded in white 96-well plates and 
treated after 24 h. Caspase-3/7 enzymatic activities were 
measured using a FLUOstar Omega plate reader (BMG 
Labtech) after adding a 1:1 ratio of CaspaseGlo 3/7 rea-
gent (Promega) to growth media and incubating for 
30 min. All values were expressed as a ratio of signal rela-
tive to solvent control.
DNA sequencing and mutation‑specific PCR
Sanger sequencing for WM35-R was commercially pro-
vided by NewGene. Total DNA was extracted using a 
DNeasy Blood & Tissue Kit (QIAGEN Inc., UK) and PCR 
used to amplify the indicated genes. PCR products were 
purified using a QIAquick PCR purification kit (QIAGEN 
Inc., UK) and sequenced by PCR based Sanger dideoxy 
chain termination.
NRAS: F-5′-CCA CAC CCC CAG GAT TCT TAC-3′, 
R-5′-AGT GTG GTA ACC TCA TTT CCC-3′
TP53(exon10): F-5′-CAT GTT GCT TTT GTA CCG 
TCA-3, R-5′-TGA AGG CAG GAT GAG AAT GGA-3′.
Mutations detected by sequencing were then investi-
gated by mutation specific PCR.
Primer pairs specific to either wild-type or mutant 
TP53 were designed as follows:
Forward wild type: 5′-CTG TTG CTG CAG ATC CGT 
GG-3′,
Forward mutant: 5′-CTG TTG CTG CAG ATC CGT 
GT-3′,
Reverse: 5′-CCT TTG ACC ATG AAG GCA GGA-3′.
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Following PCR, products were analysed on 2% agarose 
gels containing ethidium bromide and were visualised by 
UV light (G:BOX imaging system).
siRNAs and transfection
40 nM siRNA duplex against p53 was transfected by Lio-
fectamine 2000 (Thermo Fisher Scientific) in OptiMEM-
glutamax (Optimem) serum free media (Invitrogen). The 
sequences were designed as following:
SiRNA of p53 (SiP53)
Sence 5′-CCA CCA UCC ACU ACA ACU AdTdT-3′
Antisence: 5′-UAG UUG UAG UGG AUG GUG 
GdTdT-3′
SiRNA of control (SiControl)
Sense: 5′-GCG CGC UUU GUA GGA UUC GdTdT-3′
Antisense: 5′-CGA AUC CUA CAA AGC GCG CdTdT-
3′.
Statistical analysis
Data were presented as mean ± standard error of mean 
(SEM) unless otherwise stated. Statistical tests were car-
ried out using GraphPad Prism 6 software and all p-val-
ues represent paired t-tests of at least three independent 
repeats. A p-value less than 0.05 was considered as statis-
tically significant.
Results
Selection for resistant cells
SN40R2 and WM35-R cell lines with resistance to 
MDM2/p53 binding antagonists were generated by con-
tinuously exposing SJSA-1 osteosarcoma cells [20] and 
WM35 cutaneous melanoma cells to either Nutlin-3 or 
RG7388 respectively. WM35 parental cells were cultured 
in medium with 0.5 μM RG7388 in 175 cm-squared flasks 
and then RG7388 was escalated to 1, 2, 3, 5 μM gradually 
within 3  months. Paired WM35/WM35-R and SJSA-1/
SN40R2 have  BRAFV600E and  NRASQ61K mutations which 
activate the MAPK pathway and render the cells drugga-
ble by MEK or BRAF inhibitors.
WM35‑R cells are resistant to other MDM2 inhibitors
WM35-R cells were selected from a parental WM35 
culture by exposure to a final concentration of 5  μM 
RG7388. The WM35-R selected cells were treated with a 
range of RG7388 doses for 72 h in 96 well plates followed 
by SRB growth inhibition assay to confirm its resistance. 
The resistant cells underwent STR profiling to confirm 
that the selected daughter cells were derived from their 
parental cell lines (Additional file 1: Figure S1). To evalu-
ate whether WM35-R cells were cross-resistant to other 
MDM2 inhibitors, WM35-R cells were treated with 
Nutlin-3, RG7388, and HDM201 for 72  h. The growth 
inhibition curves confirmed WM35-R was cross-resist-
ant to other MDM2 inhibitors (Fig.  1a). To understand 
the mechanism of resistance to MDM2 inhibitors, immu-
noblotting and qRT-PCR were performed. Immunoblot-
ting showed p53 stabilization, followed by inductions of 
MDM2 and p21 after RG7388 and HDM201 treatment in 
WM35 but not in WM35-R, indicating functional inac-
tivation of p53 in WM35-R (Fig.  1b, c). Further investi-
gation of transcripts for p53-targeted genes by qRT-PCR 
confirmed lack of induction for CDKN1A, MDM2, 
PUMA, BAX, in WM35-R after 6- and 24-h RG7388 
treatment (Fig.  1d). To identify the most likely mecha-
nism of resistance to MDM2 inhibitors, Sanger sequenc-
ing of TP53 was carried out for WM35-R and revealed 
a homozygous TP53 point mutation (c.1001G>T) result-
ing in a p.Gly334  Val amino acid substitution in the 
p53 tetramerization domain, which was not found in 
the parental WM35 cells (Fig.  1e). To examine whether 
parental WM35 cells already harbour  p53G334V mutant 
subclones, which were not detectable by Sanger sequenc-
ing or functional assays, mutation-specific PCR was per-
formed. Primers were designed specific for this point 
mutation and revealed that the parental WM35 cell pop-
ulation harboured a low frequency of this TP53 mutant 
allele (Fig.  1f ). No evidence of the WT TP53 allele was 
found by sequence-specific PCR in the selected WM35-
R cell population. A375, a TP53 wild-type melanoma 
cell used as a negative control, showed no evidence of 
bands specific for this TP53 mutation. Therefore, it was 
concluded that a subpopulation of cells with resistance 
to MDM2 inhibitors, harbouring  p53G334V mutations, 
was present in the predominantly  p53WT WM35 paren-
tal cell culture and was selected by continuous culture in 
medium with RG7388.
SN40R2 cells selected from SJSA‑1 are resistant to all 
MDM2 inhibitors tested
SN40R2 cells were selected from a parental SJSA-1 
culture following exposure to a final concentration of 
40  μM Nutlin-3. SN40R2 was authenticated and con-
firmed by STR profiling to be derived from SJSA-1. 
TP53 mutations were found in codon 285 in SN40R2 
[20]. Cross-resistance to MDM2 inhibitors, Nutlin-3, 
RG7388 and HDM201, was also found for SN40R2 
(Fig.  2a). Western blotting showed dose-depend-
ent increases of p53 and MDM2 after treatments of 
RG7388 and HDM201 in both cells. However, MDM2 
expression in SN40R2 was much lower than SJSA-1 
and p21 induction was evident in SJSA-1, but not 
SN40R2 (Fig.  2b, c). MDM2 mRNA was not induced 
after HDM201 treatment indicating that the increase of 
MDM2 protein in SN40R2 resulted from stabilization 
Page 5 of 15Wu et al. Cancer Cell Int           (2019) 19:53 
WM35
WM35-R
Forward Reverse
Forward Reverse Wild type primers
A
37
5
W
M
35
W
M
35
R
B
la
nk
200
Mutant primers
A
37
5
W
M
35
W
M
35
R
B
la
nk
%
 G
ro
w
th
(M
ea
n
+ 
SE
M
)
%
 G
ro
w
th
(M
ea
n
+ 
SE
M
)
%
 G
ro
w
th
(M
ea
n
+ 
SE
M
)
a b
f
e
p53
MDM2
P21
Actin
WM35 WM35-R
RG7388
(µM)
M
ed
iu
m
D
M
SO
0.
03 0.
3
3.
0
M
ed
iu
m
D
M
SO
0.
03 0.
3
3.
0
d
WM35 WM35-R
HDM201
(µM)
M
ed
iu
m
D
M
SO
0.
00
3
0.
03 0.
3
M
ed
iu
m
D
M
SO
0.
00
3
0.
03 0.
3
p53
MDM2
P21
Actin
c
Fig. 1 WM35‑R was selected from WM35 for resistance to MDM2 inhibitors. a Growth inhibition curves for the response of WM35 and WM35‑R cells 
to treatment with MDM2 inhibitors for 72 h. Immunobloting of WM35 and WM35‑R following treatment with MDM2 inhibitors, RG7388 (b) and 
HDM201 (c) for 6 h. d CDKN1A, MDM2, PUMA and BAX expressions by qRT‑PCR in WM35 and WM35‑R following treatment with 0.2 µM RG7388 for 6 
and 24 h. e Chromatogram showing p53 mutations in WM35‑R. f Mutation specific PCR detecting the presence of a low frequency of mutant alleles 
in the parental WM35 cell population
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by MDM2 inhibitors rather than transactivation by p53 
stabilization (Fig.  2d). The SJSA-1 cell line was known 
to harbour an NRAS mutation. To confirm retention 
of the NRAS mutation, a potential druggable target for 
MEK inhibitors, sanger sequencing was performed and 
showed that both SJSA-1 and SN40R2 harboured a het-
erozygous NRAS point mutation (c.181C>A) resulting 
in a p.Gln61Lys amino acid substitution in the NRAS 
protein (Fig. 2e).
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Fig. 2 SN40R2 selected from SJSA‑1 was resistant to MDM2 inhibitors and retained an NRAS mutation. a Growth inhibition curves of SJSA‑1 and 
SN40R2 treated with MDM2 inhibitors for 72 h. b, c Immunobloting of SJSA‑1 and SN40R2 treated with MDM2 inhibitors, RG7388 (a) and HDM201 
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showing a c.181C>A NRAS mutation in both SJSA‑1 and SN40R2
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Growth inhibition of paired WM35 and WM35‑R cells 
by trametinib and vemurafenib
Because the paired WM35 and WM35-R harbour drug-
gable  BRAFV600E mutations (confirmed by  BRAFV600E 
specific antibody, Additional file  1: Figure S2) their 
responses to the MAPK pathway inhibitors vemu-
rafenib and trametinib were compared. Growth inhi-
bition by SRB assay showed the parental WM35 cells 
were slightly but non-significantly more sensitive, in 
terms of  GI50 level, to either trametinib or vemurafenib 
(Fig.  3a–d). However, the growth inhibition curves 
plotted with Day 0 subtraction went further below 
the seeding population level (X axis) for WM35 com-
pared with WM35-R, suggesting more cell killing and 
not just growth inhibition was induced in WM35 than 
WM35-R after trametinib and vemurafenib treatment. 
A significant difference was found when the growth 
inhibitory curves above  GI50 were compared by 2 way 
ANOVA (p = 0.0006 for trametinib and p < 0.0001 for 
vemurafenib). Immunoblotting showed dose depend-
ent suppression of phospho-ERK by 6-h treatment 
with trametinib or vemurafenib for both cell lines, 
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confirming inhibition of MAPK pathway activity 
(Fig. 3e, f ).
The effect of trametinib or vemurafenib treatment 
on cell cycle distribution and apoptosis for paired WM35 
and WM35‑R
To further explore the different responses of WM35 
and WM35-R, FACS analysis was used to evaluate the 
cell cycle distribution after MAPK inhibitor treatments. 
Both trametinib and vemurafenib induced dose depend-
ent G1 arrest in WM35 and WM35-R after 24-h (Fig. 4a, 
e, Additional file  1: Figure S3A, C, S4A, C). After 48-h 
treatments, continued G1 arrest was evident for WM35-
R, however for WM35 the proportion of cells in G1 
phase was not different to DMSO control, but there was 
an increase in sub-G1 signals (Fig. 4b, c, f, g, Additional 
file 1: Figures S3B, D, S4B, D). Both trametinib and vemu-
rafenib induced dose dependent sub-G1 signals indica-
tive of apoptosis in WM35 after 48-h treatment, which 
were significantly reduced in WM35-R (Fig. 4c, g). Cas-
pase 3/7 activity measurements supported the findings 
that trametinib and vemurafenib induced more apoptosis 
in WM35 than WM35-R (Fig. 4d, h).
WM35‑R showed much lower induction of p53‑dependent 
gene transcripts than WM35 after 24 h trametinib 
treatment
Markedly different apoptotic responses were observed 
for WM35 compared with WM35-R following treatment 
with the MAPK pathway inhibitors. This suggested the 
hypothesis that WM35-R with a non-functional p53 was 
deficient for the induction of p53-dependent apoptosis 
in response to trametinib or vemurafenib. To investigate 
this further, a panel of p53 transcriptional target genes 
was examined by qRT-PCR (Fig. 5). WM35 and WM35-
R were treated with 10 nM trametinib, a dose which had 
generated significantly different apoptotic responses. All 
the pro-apoptotic genes except TP53INP1 were induced 
to a lower extent in WM35-R than WM35 after 24-h 
trametinib treatment. Interestingly, the TP53 transcripts 
slightly increased after trametinib treatment, suggesting 
MAPK activity inhibited TP53 transcription, which was 
reversed by trametinib in WM35. The lack of p53 tran-
scriptional target gene induction in the  p53MUT WM35-
R cells was consistent with the functional inactivation 
of p53 and indicated that the parental WM35 apoptotic 
response to trametinib and vemurafenib was at least 
partly dependent on p53. However, the growth inhibitory 
response to the MAPK pathway inhibitors at lower doses 
and earlier time points was less dependent on p53. Only 
a modest increase of CDKN1A was found in WM35 but 
not in WM35-R.
SiRNA‑mediated knockdown of p53 reduced sensitivity 
and caspase 3/7 activity after trametinib and vemurafenib
To test the hypothesis that p53 is responsible for 
trametinib- and vemurafenib-induced apoptosis, p53 
levels were suppressed by siRNA in WM35 and A375. 
Immunoblotting and qRT-PCR confirmed the efficiency 
of p53 knockdown by siRNA (Fig. 6a, b, Additional file 1: 
Figure S5A, B). After siRNA-mediated knockdown of 
p53, cells were treated with trametinib and vemurafenib. 
Compared to siControl, a decrease in sensitivity to 
trametinib and vemurafenib was noted for both A375 and 
WM35 after siRNA-mediated knockdown of p53 (Fig. 6c, 
d, and Additional file 1: Figure S5C, D). Significant sup-
pression of caspase 3/7 activities was found in both cells 
after knockdown of p53 confirming that p53 was at least 
partially responsible for trametinib- and vemurafenib-
induced apoptosis (Fig. 6e, f, Additional file 1: Figure S5E, 
F).
The response of the paired SJSA‑1 and SN40R2 cell lines 
to trametinib
SJSA-1 and SN40R2 cell lines have an NRAS muta-
tion resulting in MAPK activation, suggesting possible 
response to trametinib. Growth inhibition assays showed 
both of the paired cell lines were sensitive to trametinib. 
The growth inhibition curves for both cell lines closely 
overlapped and did not go below the X axis (basal level). 
This suggested no or little apoptosis was induced after 
trametinib treatment in either cell line (Fig.  7a). Immu-
noblotting confirmed the on-target effect of trametinib, 
evidenced by suppression of phospho-ERK (Fig.  7b). 
FACS cell cycle distribution analysis showed a dose-
dependent G1 arrest response to trametinib for both cell 
lines (Fig. 7c, d) and only a small Sub-G1 fraction com-
ponent was noted after treatment for 24 and 48 h. Unex-
pectedly, the resistant SN40R2 cell showed more Sub-G1 
signals after 100 nM trametinib treatment for 48 h than 
the parental SJSA-1 cells (Fig. 7e). However, there was lit-
tle caspase 3/7 induction in both cell lines and although 
Fig. 4 The effect of trametinib or vemurafenib treatment on cell cycle distribution and apoptosis for paired WM35 and WM35‑R. Cell cycle 
distribution changes for 24 (a, e) and 48 (b, f) hour treatment with trametinib (a, b) or vemurafenib (e, f) by FACS analysis. Sub‑G1 events by FACS (c, 
g) and caspase 3/7 activity (d, h), were used as indicators of apoptosis. Statistically significant p‑values (*p < 0.05) are indicated. Data are presented 
as mean ± standard error of mean (SEM) for at least three independent repeats
(See figure on next page.)
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SN40R2 showed a slightly higher caspase 3/7 activity 
than SJSA-1, this was not statistically significant (Fig. 7f ). 
The sub-G1 observation for the 100  nM response by 
FACS analysis was not mirrored by the caspase 3/7 activ-
ity following that dose of trametinib.
Discussion
In the current study, the growth inhibitory and cytotoxic 
activities of MAPK inhibitors, trametinib and vemurafenib, 
were investigated with paired TP53WT and TP53MUT cell 
lines. The results demonstrated that TP53 mutant cells 
selected for resistance to MDM2 inhibitors neverthe-
less retained sensitivity to targeted treatment with MAPK 
inhibitors. Trametinib and vemurafenib showed simi-
lar growth inhibitory effects on paired WM35/WM35-R 
and SJSA-1/SN40R2 cells. However, WM35 underwent 
p53-dependent apoptosis after trametinib and vemurafenib 
treatment, whereas SJSA-1, which is MDM2 amplified, 
did not undergo a p53-dependent apoptotic response to 
trametinib, although growth inhibition was observed. A 
diagrammatic summary is shown in Fig. 8.
BA
X
TN
FR
SF
10
B
TP
53
IN
P1 FA
S
PIG
3
PU
MA
FD
XR AE
N
CD
KN
1A
MD
M2 TP
53
Fo
ld
s 
ch
an
ge
d
BA
X
TN
FR
SF
10
B
TP
53
IN
P1 FA
S
PIG
3
PU
MA
FD
XR AE
N
CD
KN
1A
MD
M2 TP
53
Fo
ld
s 
ch
an
ge
d
a
b
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Data are presented as mean ± standard error of mean (SEM) for three independent repeats
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Cell lines selected for resistance to MDM2 inhibitors had 
TP53 mutations and were cross‑resistant to other MDM2 
inhibitors
Most in  vitro studies reported have shown that cells 
selected for resistance to MDM2 inhibitors harbour 
p53 mutations and show a deficiency of p53-dependent 
apoptosis in response to MDM2 inhibitor treatment 
[19, 20, 23]. One recent study used piggyBac transpo-
son insertional mutagenesis in a cohort of allografts with 
an underlying CDKN2A deletion, to anticipate resist-
ance mechanisms which might occur during treatment 
with the MDM2-p53 inhibitor HDM201. The most fre-
quent mechanisms conferring resistance converged on 
direct (TP53 mutations) or indirect (gain-of-function of 
MDM4, TP63, TP73) loss-of-function inactivation of the 
p53 protein. In addition, activation of the anti-apoptotic 
B-cell lymphoma-extra large (Bcl-xL) gene was observed 
[24]. Although MDM2 inhibitors (Nutlin-3, RG7388) 
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were previously reported as a modulators of MDR-1(p-
glycoprotein) [25, 26] and MDR-1-overexpressed cells 
showed decreased sensitivity to Nutlin-3 [25], there are 
no reports that selection for resistance to MDM2 inhibi-
tors results from amplification and/or overexpression of 
genes encoding multidrug resistance proteins.
Consistent with previous reports, both cell lines 
selected for resistance to MDM2 inhibitors investigated 
in the current study have TP53 mutations. The selec-
tion and characterisation of SN40R2, which has been 
reported previously by our group [20] and of WM35-
R described here, are the first reported  p53MUT cell 
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lines which have been selected in  vitro for resistance 
to RG7388 [22, 27], a clinically relevant more potent 
and specific MDM2 inhibitor than Nutlin-3 [19, 20, 23] 
and MI-63 [20] which were used in previous studies. 
In contrast to another study which was based on p53 
mutation which had been generated de novo [27], the 
current study investigated the selection of cells resist-
ant to MDM2 inhibitors from a parental culture of 
WM35 melanoma cells. This resulted in the selection 
of a p53 mutated subpopulation. Most reported TP53 
mutations are located in the DNA binding domain, 
however the WM35-R resistant sub-line has an uncom-
monly reported  p53G334V point missense mutation in 
a critical residue the tetramerization domain of p53, 
which consists of a α-strand (Glu326–Arg333), a tight 
turn (Gly334), and a β-helix (Arg335–Gly356) [28]. In 
the wild-type tetramerization domain, Gly334 facili-
tates the formation of a sharp turn connecting the 
β-strand with the α-helix and adopts a backbone con-
formation that would be energetically unfavorable for a 
non-glycine residue, indicating that mutation of Gly334 
is expected to result in structural distortions [29]. The 
Gly334 mutant p53 protein exhibits a global decrease 
in DNA binding and transactivation activity [30]. In the 
current study, WM35-R with such a  p53G334V mutation 
lost its transactivation activity, evidenced by no induc-
tion of downstream targets of p53 and consequent 
cross-resistance to other MDM2 inhibitors. For the 
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p53
p53 mutation
MAPK inhibition
p53
p53 mutation
MDM2 overexpression
Cell cycle arrest
Apoptosis
Cell cycle arrest
Cell cycle arrest
Apoptosis
a
b
Fig. 8 Proposed model for MAPK inhibition in paired TP53WT and TP53MUT cell lines selected for resistance to MDM2 inhibitors. WM35‑R (a) and 
SN40R2 (b) were selected from WM35 and SJSA‑1 respectively and both were sensitive to growth inhibition by MAPK pathway inhibition. The 
TP53MUT cells lost p53‑dependent apoptosis but retained p53‑independent cell cycle arrest and growth inhibition in response to inhibition of 
the MAPK pathway. SJSA‑1 showed minimal p53‑dependent apoptosis in response to MAPK pathway inhibition, plausibly resulting from p53 
suppression by overexpression of MDM2
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other resistant cell line, SN40R2, detailed characteris-
tics and discussions have been addressed in our previ-
ous publication [20].
TP53MUT cells selected for resistance to MDM2 inhibitors 
retain sensitivity to growth inhibition by MAPK pathway 
inhibitors but a reduced p53‑dependent apoptotic 
response to them
To investigate whether cross-resistance occurs between 
MDM2/p53 binding antagonists and MAPK pathway 
inhibitors, trametinib and vemurafenib, paired WM35/
WM35-R and SJSA-1/SN40R2 cells were tested and 
showed similar growth inhibitory effects for the paired 
cell lines. This showed that a growth inhibitory response 
to MAPK pathway inhibition was maintained in the TP53 
mutant cell lines selected for resistance to MDM2 inhibi-
tors. However, more p53-regulated apoptosis was found 
in WM35 than WM35-R, supported by sub-G1 fraction 
on FACS analysis and caspase 3/7 activity, indicating 
that trametinib and vemurafenib acted on the cells par-
tially through a p53-regulated pro-apoptotic pathway, 
particularly at higher doses. The interaction between the 
MAPK pathways and the p53/MDM2/MDMX network 
are tightly regulated [31]. A murine model study showed 
that the RAS/RAF pathway activated the transcription 
of both MDM2 and its inhibitor  p19ARF [32]. The level of 
p53 was determined by opposing effects of RAF-induced 
 p19ARF and MDM2. In the absence of  p19ARF or when the 
induction of MDM2 exceeds that of  p19ARF (a common 
situation in many human cancers), the RAS/RAF/MEK/
ERK pathway attenuates p53. Another study supported 
this finding by using a RAS inhibitor, farnesylthiosalicylic 
acid (FTS), which increased p53 expression through both 
downregulation of MDM2 and transcriptional activation 
of p53 [33]. Consistent with these observations, in the 
current study trametinib treatment induced transcripts 
of TP53 as well as CDKN1A and p53-regulated pro-apop-
totic genes in WM35. CDKN1A only slightly increased in 
WM35 but not in WM35-R indicating that trametinib-
induced G1 arrest was mainly p53/p21-independent, 
which is consistent with a previous report that MEK inhi-
bition in melanoma cells resulted in p27 regulated G1 
arrest rather than via p21 [34].
Differences between WM35 and SJSA‑1
In contrast to the different responses between WM35 
and WM35-R, the SJSA and SN40R2 cell lines did not 
show such differences. Little apoptosis was found in the 
parental TP53 wild-type SJSA-1 cells, which was differ-
ent to WM35. SJSA-1 is a MDM2 amplified osteosar-
coma cell line in which the function of p53 is suppressed 
by overexpressed MDM2, whereas WM35 has no MDM2 
amplification and lower expression of MDM2 protein 
(Additional file 1: Figure S6). This possibly explains why 
little p53-dependent apoptosis was found after trametinib 
treatment of SJSA-1 and SN40R2. The MDM2 suppres-
sion of p53 rather than RAS mutation is a main driver 
target in SJSA-1, evidenced by the significant induction 
of caspase 3/7 activity after MDM2 inhibitor treatment 
(Additional file 1: Figure S7). The combination of MAPK 
and MDM2 inhibitors as a strategy for cancers with 
wild-type p53 and mutations of RAS/RAF merits further 
exploration.
Conclusions
In conclusion, there was restricted cross-resistance 
between MDM2/p53 binding antagonists and MAPK 
inhibitors indicating that resistant cancer cells potentially 
selected by MDM2 inhibitors can nevertheless be treated 
with MAPK inhibitors if the cells have druggable muta-
tions driving the MAPK pathway.
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